Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Genmab A/S (OTC: GMXAY).

Full DD Report for GMXAY

You must become a subscriber to view this report.


Recent News from (OTC: GMXAY)

Recent analyst action in Europe - healthcare
Fresenius Medical Care ( FMS +1.5% )( OTCPK:FMCQF )( OTCPK:FSMEM ) assumed with Hold rating and €82 price target at Jefferies. More news on: Fresenius Medical Care AG & Co. KGAA, Fresenius Medical Care AG & Co KGaA, Fresenius Medical Care Holdings, Healthcare stocks news, ...
Source: SeekingAlpha
Date: September, 25 2018 11:38
Darzalex combo therapy OK'd in Europe for first-line multiple myeloma
As expected, the European Commission approves Johnson & Johnson (NYSE: JNJ ) unit Janssen Biotech's DARZALEX (daratumumab), combined with Takeda Pharmaceutical's ( OTCPK:TKPYY ) VELCADE (bortezomib), melphalan and prednisone, for the treatment of adult patients with multiple myeloma in...
Source: SeekingAlpha
Date: August, 31 2018 08:56
STOXX 600 Earnings Roundup - Week Ending August 10, 2018
By Tajinder Dhillon 18Q2 earnings season is underway with 34 companies reporting last week ending August 10, 2018. Exhibit 1 provides a summary of reporting results. Exhibit 1: Earnings Season Results Overall Recap Of the companies that reported last week, 44% beat EPS expectatio...
Source: SeekingAlpha
Date: August, 14 2018 02:46
Genmab A/S 2018 Q2 - Results - Earnings Call Slides
The following slide deck was published by Genmab A/S in conjunction with their 2018 Q2 earnings Read more ...
Source: SeekingAlpha
Date: August, 09 2018 15:48
Genmab's pain is Verastem's gain, up 5%
Verastem ( VSTM +5.1% ) is up on average volume in apparent response to Genmab's ( OTCPK:GNMSF )( OTCPK:GMXAY ) failed late-stage study of Arzerra (ofatumumab) in indolent B-cell non-Hodgkin lymphoma. Ofatumumab, a CD-20-directed monoclonal antibody, is currently approved in the U.S. t...
Source: SeekingAlpha
Date: May, 24 2018 11:45
Genmab's ofatumumab flunks late-stage NHL study
Genmab A/S ( OTCPK:GNMSF )( OTCPK:GMXAY )  announces that a Phase 3 clinical trial evaluating Arzerra (ofatumumab) plus bendamustine in patients with indolent B-cell non-Hodgkin lymphoma (iNHL) who have not responded to Roche's Rituxan (rituximab) failed to demonstrate a statistically ...
Source: SeekingAlpha
Date: May, 24 2018 10:40
Genmab (GMXAY) Presents At 2018 UBS Global Healthcare Conference - Slideshow
The following slide deck was published by Genmab A/S ADR in conjunction with this Read more ...
Source: SeekingAlpha
Date: May, 23 2018 14:47
Stocks To Watch: Apple, FOMC And China On Tap
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. U.S. Treasury Secretary Steven Mnuchin is scheduled to lead a delegation to China f...
Source: SeekingAlpha
Date: April, 28 2018 09:13
Genmab (GNMSF) Presents At Deutsche Bank's Depositary Receipts Virtual Investor Conference - Slideshow
The following slide deck was published by Genmab A/S in conjunction with this Read more ...
Source: SeekingAlpha
Date: March, 26 2018 15:37
Genmab A/S webcast presentation now available for on-demand viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference
Genmab A/S webcast presentation now available for on-demand viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference Canada NewsWire COPENHAGEN, Denmark, March 26, 2018 Company invites individual and institutional investors, as well as advisors, to log-on to view...
Source: Canada Newswire
Date: March, 26 2018 08:35

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-1316.2916.2116.3016.1666,602
2018-12-1215.8815.99516.06415.8858,275
2018-12-1115.6115.4515.6515.37236,560
2018-12-1015.6215.7515.8315.5776,844
2018-12-0715.4615.18515.4715.1182,668

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1310,04166,53715.0909Cover
2018-12-128,39358,27514.4024Cover
2018-12-1115,604236,5606.5962Cover
2018-12-1022,57576,84429.3777Cover
2018-12-0733,66679,86842.1521Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on GMXAY.


About Genmab A/S (OTC: GMXAY)

Logo for Genmab A/S (OTC: GMXAY)

Genmab is an international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.

 

Contact Information

 

 

Current Management

  • Jan G. J. van de Winkel / President, CEO
  • David A. Eatwell / CFO
  • Rachel Curtis Gravesen / SVP, Inv. Rel.

Current Share Structure

  • Market Cap: $10,703,733,822 - 03/15/2018
  • Issue and Outstanding: 51,052,818 - 07/30/2013

 


Recent Filings from (OTC: GMXAY)

Post-effective amendment to a previously filed F-6
Filing Type: F-6 POSFiling Source: edgar
Filing Date: April, 13 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: December, 22 2017
Registration of depository shares evidenced by American Depository Receipts
Filing Type: F-6Filing Source: edgar
Filing Date: December, 18 2017

 

 


Daily Technical Chart for (OTC: GMXAY)

Daily Technical Chart for (OTC: GMXAY)


Stay tuned for daily updates and more on (OTC: GMXAY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: GMXAY)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GMXAY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of GMXAY and does not buy, sell, or trade any shares of GMXAY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/